16 research outputs found

    Estudio de los receptores adrenérgicos α2 y la proteína espinofilina en la corteza prefrontal postmortem de sujetos con esquizofrenia

    Get PDF
    221 p.La esquizofrenia (SZ) es una enfermedad mental crónica e incapacitante. Su etiología es de carácter multifactorial teniendo un componente genético y otro ambiental que intervienen en su aparición y el curso de la enfermedad. Los primeros síntomas que aparecen son los cognitivos y no tienen tratamiento. La hipótesis principal de esta Tesis Doctoral se basa en que los receptores adrenérgicos α2A (α2A-AR,) de la corteza prefrontal (CPF) son hipofuncionantes y pueden estar relacionados con los déficits cognitivos de la patología. Para ello se ha estudiado en la CPF de humanos postmortem (1) la expresión proteica de los α2A-AR, y α2C-AR en el sinaptosoma, la fracción presináptica y postsináptica, (2) la funcionalidad de los α2-AR, (3) la expresión génica de los genes ADRA2A y ADRA2C, (4) modificaciones epigenéticas en los promotores de los genes ADRA2A y ADRA2C y (5) evaluar la expresión proteica de espinofilina, como marca de espinas dendríticas, en el sinaptosoma, la fracción presináptica y postsináptica. Todo ello se ha realizado comparando cerebros de sujetos controles y sujetos con esquizofrenia, evaluando la influencia de los fármacos antipsicóticos (AP) en todo ello. Los resultados más destacables de esta Tesis Doctoral son (1) el aumento de la expresión proteica de los α2A-AR en la fracción postsináptica en sujetos con SZ y AP, (2) una hipofunción de los α2-AR sujetos con SZ y AP, (3) una disminución de la expresión génica del ADRA2A sujetos con SZ y AP y de ADRA2C en SZ, (4) alteración en modificaciones epigenéticas en los dos promotores en SZ y (5) una disminución en la expresión proteica de espinofilinaen la fracción postsináptica en sujetos con SZ y AP. Estos resultados sugieren que los AP pueden alterar la funcionalidad y expresión de los α2-AR y la expresión de dendritas sinápticas en la CPF de sujetos con SZ

    Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Get PDF
    [EN] Postsynaptic alpha(2A)-adrenoceptor density is enhanced in the dorsolateral prefrontal cortex (DLPFC) of antipsychotic-treated schizophrenia subjects. This alteration might be due to transcriptional activation, and could be regulated by epigenetic mechanisms such as histone posttranslational modifications (PTMs). The aim of this study was to evaluate ADRA2A and ADRA2C gene expression (codifying for alpha(2)-adrenoceptor subtypes), and permissive and repressive histone PTMs at gene promoter regions in the DLPFC of subjects with schizophrenia and matched controls (n = 24 pairs). We studied the effect of antipsychotic (AP) treatment in AP-free (n = 12) and AP-treated (n = 12) subgroups of schizophrenia subjects and in rats acutely and chronically treated with typical and atypical antipsychotics. ADRA2A mRNA expression was selectively upregulated in AP-treated schizophrenia subjects (+93%) whereas ADRA2C mRNA expression was upregulated in all schizophrenia subjects (+53%) regardless of antipsychotic treatment. Acute and chronic clozapine treatment in rats did not alter brain cortex Adra2a mRNA expression but increased Adra2c mRNA expression. Both ADRA2A and ADRA2C promoter regions showed epigenetic modification by histone methylation and acetylation in human DLPFC. The upregulation of ADRA2A expression in AP-treated schizophrenia subjects might be related to observed bivalent chromatin at ADRA2A promoter region in schizophrenia (depicted by increased permissive H3K4me3 and repressive H3K27me3) and could be triggered by the enhanced H4K16ac at ADRA2A promoter. In conclusion, epigenetic predisposition differentially modulated ADRA2A and ADRA2C mRNA expression in DLPFC of schizophrenia subjects.This work was supported by Spanish MINECO (grant SAF2013-48586-R) and Basque Government (grant IT1211/19). The authors would like to thank the staff members of the Basque Institute of Legal Medicine for their cooperation in the study

    Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity

    Get PDF
    Compounds with excellent receptor engagement displaying alpha(2)-AR antagonist activity are useful not only for therapeutic purposes (e.g. antidepressants), but also to help in the crystallization of this particular GPCR. Therefore, based on our broad experience in the topic, we have prepared eighteen di-aryl (phenyl and/or pyridin-2-yl) mono- or di-substituted guanidines and 2-aminoimidazolines. The in vitro alpha(2)-AR binding affinity experiments in human brain tissue showed the advantage of a 2-aminoimidazolinium cation, a di-arylmethylene core, a conformationally locked pyridin-2-yl-guanidine and a di-substituted guanidinium to achieve good alpha(2)-AR engagement. After different in vitro [S-35]GTP gamma S binding experiments in human prefrontal cortex tissue, it was possible to identify that compounds 7a, 7b and 7c were alpha(2)-AR partial agonist, whereas 8h was a potent alpha(2)-AR antagonist. Docking and MD studies with a model of alpha(2A)-AR and two crystal structures suggest that antagonism is achieved by compounds carrying a di-substituted guanidine which substituent occupy a pocket adjacent to TM5 without engaging S200(5.42) or S204(5.46), and a mono-substituted cationic group, which favorably interacts with E94(2.65). (c) 2020 Elsevier Masson SAS. All rights reserved.Thanks are given to the School of Chemistry at Trinity College Dublin (M.McM.) and to the Irish Research Council (A.K. -GOIPG/2014/457-and H.B.M. -GOIPG/2017/834-) for postgraduate support. This study was also supported by the Ministerio de Economia y Competitividad of Spain (SAF2013-48586-R) and the Basque Government (IT1211-19). The authors would like to thank the staff members of the Basque Institute of Legal Medicine for their cooperation in the study

    Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

    Get PDF
    Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer’s disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson’s disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration

    A bicyclic α-iminophosphonate improves cognitive decline in 5xFAD murine model of neurodegeneration

    Get PDF
    I2 receptors (I2-IR) are widely distributed in the central nervous system. I2-IR ligands are associated with a neuroprotective effect but, as I2-IR structure remains unknown, the discovery of better and more selective ligands is necessary to understand the pharmacological and molecular implications of I2-IR. Recently, we described a new imidazoline-structure family which showed high affinity and selectivity for I2-IR. In vivo studies in mice indicated a neuroprotective role and revealed beneficial effects in behaviour and cognition with a murine model of neurodegeneration, senescence-accelerated prone mouse (SAMP8). Herein, we report a novel non-imidazoline-structure of bicyclic α-iminophosphonates family with high affinities for I2-IR. In vivo studies in 5X-FAD mice (a transgenic representative model of AD) and SAMP8 mice (a model of neurodegeneration linked to aging) showed an improvement in behaviour and cognition, a reduction of AD hallmarks and of neuroinflammation markers for the mice treated with the lead compound B06. After evaluating several pathways associated with neurodegeneration, we demonstrated that CaN pathway plays a critical role on the neuroprotective effects of I2-IR ligands on SAMP8 mice model. To rule out warnings of the novel family, we calculated DMPK and physicochemical properties for the novel bicyclic α-iminophosphonates. As well, we carried out drug metabolism, safety studies and in vivo pharmacokinetics for lead compound B06. In summary, we present a novel family of I2-IR ligands, its effectiveness in in vivo models and the possible neuroprotective molecular mechanism mediated by them. This highlights that the modulation of I2-IR by bicyclic α-iminophosphonates may open a new therapeutic venue for unmet neurodegenerative conditions

    Bicyclic alfa-iminophosphonates as high affinity imidazoline I2 receptor ligands for Alzheimer's disease

    Get PDF
    Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffered from neurodegenerative disorders, are orphan from the structural point of view and new I2-IR ligands are urgently required for improving their pharmacological characterization. We report the synthesis and 3D-QSAR studies of a new family of bicyclic α-iminophosphonates endowed with relevant affinities for human brain I2-IR. Acute treatment in mice with a selected compound significantly decreased the FADD protein in the hippocampus, a key marker in neuroprotective actions. Additionally, in vivo studies in the familial Alzheimer's disease 5xFAD murine model revealed beneficial effects in behavior and cognition. These results are supported by changes in molecular pathways related to cognitive decline and Alzheimer's disease. Therefore bicyclic α-iminophosphonates are tools that may open new therapeutic avenues for I2-IR, particularly for unmet neurodegenerative conditions

    Characterization of hevin (SPARCL1) immunoreactivity in postmortem human brain homogenates

    No full text
    International audienceHevin is a matricellular glycoprotein that plays important roles in neural developmental processes such as neuronal migration, synaptogenesis and synaptic plasticity. In contrast to other matricellular proteins whose expression decreases when development is complete, hevin remains highly expressed, suggesting its involvement in adult brain function. In vitro studies have shown that hevin can have different post-translational modifications. However, the glycosylation pattern of hevin in the human brain remains unknown, as well as its relative distribution and localization. The present study provides the first thorough characterization of hevin protein expression by Western blot in postmortem adult human brain. Our results demonstrated two major specific immunoreactive bands for hevin: an intense band migrating around 130 kDa, and a band migrating around 100 kDa. Biochemical assays revealed that both hevin bands have a different glycosylation pattern. Subcellular fractionation showed greater expression in membrane-enriched fraction than in cytosolic preparation, and a higher expression in prefrontal cortex (PFC) compared to hippocampus (HIP), caudate nucleus (CAU) and cerebellum (CB). We confirmed that a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) and matrixmetalloproteinase 3 (MMP-3) proteases digestion led to an intense double band with similar molecular weight to that described as SPARC-like fragment (SLF). Finally, hevin immunoreactivity was also detected in human astrocytoma, meningioma, cerebrospinal fluid and serum samples, but was absent from any blood cell type

    The Matricellular Protein Hevin Is Involved in Alcohol Use Disorder

    Get PDF
    Astrocytic-secreted matricellular proteins have been shown to influence various aspects of synaptic function. More recently, they have been found altered in animal models of psychiatric disorders such as drug addiction. Hevin (also known as Sparc-like 1) is a matricellular protein highly expressed in the adult brain that has been implicated in resilience to stress, suggesting a role in motivated behaviors. To address the possible role of hevin in drug addiction, we quantified its expression in human postmortem brains and in animal models of alcohol abuse. Hevin mRNA and protein expression were analyzed in the postmortem human brain of subjects with an antemortem diagnosis of alcohol use disorder (AUD, n = 25) and controls (n = 25). All the studied brain regions (prefrontal cortex, hippocampus, caudate nucleus and cerebellum) in AUD subjects showed an increase in hevin levels either at mRNA or/and protein levels. To test if this alteration was the result of alcohol exposure or indicative of a susceptibility factor to alcohol consumption, mice were exposed to different regimens of intraperitoneal alcohol administration. Hevin protein expression was increased in the nucleus accumbens after withdrawal followed by a ethanol challenge. The role of hevin in AUD was determined using an RNA interference strategy to downregulate hevin expression in nucleus accumbens astrocytes, which led to increased ethanol consumption. Additionally, ethanol challenge after withdrawal increased hevin levels in blood plasma. Altogether, these results support a novel role for hevin in the neurobiology of AUD
    corecore